Frequently Used Allopathic and Traditional Medicine for COVID-19 Treatment and Feasibility of Their Integration

Aditya Upadhayay¹, Gopal Patel², Dharm Pal³, and Awanish Kumar⁴

ABSTRACT  To date, no satisfactory treatment for COVID-19 is available. This review reported few recent updates regarding the drugs (allopathy/traditional medicines) used for the treatment of COVID-19 concerning clinical studies. Content of the article spotlight the contribution of allopathic and Ayurvedic drugs to the scientific basis for utilization as a potential therapy against COVID-19 infection and provide new insights on the integration of allopathy and traditional medicine. It advocated the combination of these two systems of treatment will ascertain their integrations, and there would be a good possibility and scope for developing a model of integration in the management of COVID-19. Provided discussion may help researchers, physicians, and healthcare policymakers to encourage for effective and integrated use of allopathic and Ayurvedic medicines to control the COVID-19 pandemic more effectively.

KEYWORDS  COVID-19, allopathy, traditional medicine, integration, promising therapy

At present, novel coronavirus (COVID-19) has become a pandemic problem.¹⁻³ Coronavirus was originally transmitted from animal/bird to human, and was rapidly transmitted from an infected to healthy human through air droplets released during coughing/sneezing and get entry into lung of a healthy person. Thus, coronavirus has been termed as an airborne infectious problem.⁴⁻⁵ As per World Health Organization report (20th December, 2021), 275,063,925 COVID-19 cases had been recorded in world.⁶⁻⁷

Gammacoronavirus/deltacoronavirus infect birds/mammals but seldom infect human.⁶⁻¹⁰ Phylogenetic/genomic analyses showed that COVID-19 genome has more similarity with BAT-SARS-coronavirus.¹¹⁻¹² Coronavirus genome (29,903 nucleotides) contains two untranslated regions at 5'-end and 3'-end and 11 open reading frames. The 4 structural proteins are spike (S), matrix (M), envelope (E), and nucleocapsid (N)-protein.¹³⁻¹⁴ Spike protein of SARS-CoV-2 binds with host ACE2 receptor to enter.¹⁵⁻¹⁶ Consequently, COVID-19 delivers RNA into host’s cytoplasm. After translation, the ORF1a and ORF1ab encode polypeptide to the formation of replication transcriptions complex, which is responsible for replication of the viral genome thus producing (−)RNA genome by using viral (+)RNA as template. Sub-genomic RNA is produced by fragmented transcription which also leads to the formation of structural proteins.¹⁷⁻¹⁸ Finally, all components assembled in the host's cytoplasm and new virions release from infected host cell via exocytosis (Figure 1). COVID-19 produces 8 antagonist molecules or chemicals that can overcome/inhibit the host immune response.¹⁸⁻²⁰ At current, no curative drugs are available for COVID-19.²¹⁻²³ This article summarized the current use of allopathic/traditional medicine and their integration for COVID-19.

Allopathic Medicines Used for Treatment of COVID-19

Many allopathic antiviral drugs were used for controlling the COVID-19 infection. In the current scenario, chloroquine, hydroxychloroquine, remdesivir, lopinavir/ritonavir, and ribavirin are used for COVID-19 treatment.²⁴ But these drugs are not approved as antiviral drugs because a specific mechanism of action against COVID-19 infection is not deciphered yet. Various studies suggested the uses of different
For the treatment of COVID-19 infection but not a single proven antiviral drug is available against COVID-19 (Table 1). Therefore, we discussed some allopathic drugs that were given to COVID-19 patients during the course of treatment. Although their antiviral mechanism for COVID-19 is not known, COVID-19 patients got relief using the following drugs.

**Chloroquine and Hydroxychloroquine**

Chloroquine/hydroxychloroquine have satisfactory results in COVID-19 treatment. It works as a malarial drug since 1990. Their mode of action is based on pH mechanisms. These drugs are weak base and accumulate in cell organelles like lysosomes and endosomes. After drug accumulation, an increase in pH within the cell organelles inhibits the endosomal process followed by the degradation of cellular enzymes. Altered pH is responsible for inhibition of the viral replication and also affects the endocytosis process. Chloroquine and hydroxychloroquine also play a critical role in the reduced glycosylation process of angiotensin converting enzyme 2 (ACE2) receptors that results in inhibition of the COVID-19 binding with host cells. A recent clinical study suggested that chloroquine is a better drug as compared than other drugs for the treatment of COVID-19. In this clinical study, chloroquine (500 mg) was given to the COVID-19 infected patients twice a daily for 10 days. Consequently, patients had relief after the chloroquine treatment but other non-chloroquine treated patients have not felt relieved. Another study reported that drug’s outcome was more effective for controlling pneumonia, lung infection and improving other symptoms in COVID-19 infected patients.  

**Remdesivir, Ritonavir/Lopinavir, Umifenovir, Favipiravir, and Oseltamivir**

Remdesivir (GS-5734: adenosine nucleoside analog) was originally made for the treatment of the Ebola and Marburg viruses. However, it is also being used for treatment of COVID-19 infection because of its specific action against the RNA virus. After metabolism inside the cell, the prodrug is transformed into the active "nucleotide triphosphate" metabolite form, which is responsible for inhibiting the viral RNA-dependent RNA polymerase. Thus, it prevents the synthesis of viral RNA and virus replication inside the cells.

Ritonavir/Lopinavir used in HIV, are responsible for the inhibition of protease enzymes to prevent viral infection. Protease enzyme also plays an important role in the generation of viral cells and genome maturation. A recent study suggests that these drugs may be useful for controlling the COVID-19 infections. In contrast, another clinical study shows the result that no benefit was observed by the Ritonavir/Lopinavir
drug of COVID-19 infection. (37)

Umifenovir/Arbidol drug was developed for the treatment of the influenza virus. It acts as a blocking agent for the virus and cell membrane fusion process and also inhibits the virus-endosome fusion process. (32) This drug may be useful for the treatment of COVID-19 infection.

Favipiravir/6-fluro-3-hydroxy-2-pyrazine-carboxamide was used for the treatment of RNA virus-like avian influenza virus. It entered into the infected cell by endocytosis process and converted into active form as a favipiravir-ribofuranosyl phosphate by the phosphorylation process. (33) This drug expresses the inhibitory effect on RNA-dependent RNA polymerase (RdRP). Consequently, RNA replication gets blocked. Recent study suggests that favipiravir may be another approach for the treatment of COVID-19 infection. (33)

Oseltamivir drug was originally made for the treatment of influenza A and B and acts by preventing the proliferation of viruses in the human. (34) Various clinical trials are ongoing for controlling the COVID-19 infection by oseltamivir drug alone and with other drug combinations.

### Table 1. List of Allopathic and Ayurvedic Drugs Used for Management of COVID-19 Infected Patients

| Type of medicine | Name of drug     | Molecular formula/compounds/ingredients | Molecular weight (g/mol) | Possible mechanism                                      | Reference |
|------------------|------------------|------------------------------------------|--------------------------|--------------------------------------------------------|-----------|
| Allopathic       | Hydroxychloroquine | C_{18}H_{26}ClN_{3}O                       | 335.9                    | pH alteration, inhibiting replication                  | 26        |
|                  | Remdesivir       | C_{27}H_{35}N_{6}O_{8}P                    | 602.6                    | Inhibiting replication                                 | 29        |
|                  | Ritonavir/Lopinavir | C_{27}H_{48}N_{6}O_{5}S_{2}              | 720.9                    | Inhibition of protease enzyme to prevent the viral infection | 36        |
|                  | Umifenovir       | C_{22}H_{25}BrN_{2}O_{3}S                 | 477.4                    | Blocking agent for virus and cell membrane fusion process | 32        |
|                  | Favipiravir      | C_{3}H_{6}F_{3}N_{2}O_{5}                 | 157.1                    | Reducing viral production                             | 33        |
| Corticosteroids  |                 |                                          |                          | Releasing inflammation in lungs                        | 38        |
| Corticosteroids  |                 |                                          |                          | Reducing inflammation in lungs                        | 38        |
| Oseltamivir      |                 | C_{16}H_{28}N_{2}O_{4}                    | 312.4                    | Preventing proliferation of viruses in human body      | 34        |
| Ayurvedic        | Ayush-64         | Chirayata, kuberaksha seeds, katuki root, saptaparna stem | –                       | Working as an immune booster                           | 41        |
|                  | Withania somnifera | Anaferine, anahygrine, beta-sisterol, chlorogenic acid, cysteine, scopoletin, cuscohygrine, pseudotropine | –                       | Working as an immune booster                           | 45        |
|                  | Licorice (Glycyrrhiza glabra) | –                                | –                       | Working as an immune booster                           | 46        |
|                  | Allum sativum    | –                                        | –                       | Working as an immune booster                           | 49        |
|                  | Phyllanthus emblica | –                                | –                       | Working as an immune booster                           | 49        |
|                  | Coronil          | Withania somnifera, Tinospora cordifolia, Ocimum sanctum, Cassia fistuls, Piper nigrum, Eclipta alba | –                       | Working as an immune booster                           | 45        |
|                  | Ayush kwath      | Ocimum sanctum, Cinnamomum zeylanicum, Piper nigrum, Zingiber officinale | –                       | Working as an immune booster                           | 53        |
|                  | Samshamani vati  | Tinospora cordifolia                    | –                       | Working as anti-inflammatory                            | 54        |
| Chinese medicine | Qingfei Paidu Decoction (清肺排毒), Yupingfeng Powder (玉屏风散), Huoxiang Zhengqi Powder (藿香正气散), and Lianhua Qingwen Capsule (连花清瘟胶囊) | –                       | –                       | Working as an immune booster and also anti-inflammatory | 40        |

Corticosteroids

Various corticosteroids are used for the treatment of COVID-19 infections like dexamethasone, prednisone, methylprednisolone, hydrocortisone, etc. Corticosteroids are mainly useful for lower respiratory infections and other allergies. The various studies suggest that corticosteroids are helpful to remove the inflammation from lungs during COVID-19 infection. Dexamethasone can control COVID-19 infection from...
ventilated patients and on oxygen support system patients. Dexamethasone showed a 35% decline in the death rate from COVID-19 patients on ventilated patients and also reduce a 20% death rate on oxygen support system patients. Thus, dexamethasone showed the effective result against COVID-19 infection. Methylprednisolone is another effective corticosteroid against COVID-19 infection. A study demonstrated that methylprednisolone high dose was effective on COVID-19 patients as compared to dexamethasone. It also reduces the recovery time of COVID-19 patients. It is capable to control chronic pneumonia infection during the COVID-19 infection. All the above studies provide strong evidence that corticosteroids are very effective against COVID-19 infection throughout the world.

All above discussed allopathic drugs were used against COVID-19 but these drugs also have shown limitation like require more recovery time and not effective to every stage of COVID-19 infection. These drugs were adopted into routine care for hospitalized COVID-19 patients at many hospitals. However, lack of evidence on their safety and efficacy further recommends extensive clinical trials for evaluating these drugs as an impending treatment for COVID-19 patients. Some clinical trials of these antiviral drugs were carried out but they were limited to the hospitalized patients. Hence more research is needed to develop some more efficacious antiviral molecules along with their specific mode of action and other evidence.

Traditional Medicines Used for COVID-19 Treatment

India has the old traditional medicine system known as the ayurvedic drug system. Indians have been using ayurvedic drugs as traditional medicines for treatment of various antiviral and other diseases but research and development on dosage, processing, and techniques are still lacking in the field of traditional medicine as compared to allopathic medicine. It is well-known that traditional medicine mainly improves the human immune system and provides the immunity against various viral and bacterial infections, therefore, this system is gaining faith and public are shifting from allopathic drug to traditional drugs due to side effect of the synthetic product of allopathy. In present situation, human beings are facing COVID-19 infections for which Indian ayurvedic drugs can prove helpful for improving immunity of the human body (Table 1). Chinese medicine (CM) is well known traditional medicine and it showed a highly therapeutic role to control the SARS infection. Following are the traditional medicine that was used for the treatment of infection during COVID-19 pandemic.

Ayurvedic Medicine
Ayush-64
Ayush-64 is an anti-malarial ayurvedic drug. It is formulated by a combination of the chirayata, kuberaksha seeds, katuki root, and saptaparna stem. A study suggests that it also worked as an anti-viral drug and removed the influenza-like illness. In this study, a total of 38 patients were enrolled with suffered from influenza infection. After hospitalization, patients were treated with Ayush-64 for 1 week. Patients showed the improvement of influenza-like illness symptoms. Ayush-64 may be used as a supportive drug in COVID-19 infection because Ayush-64 had shown good results in malarial and viral infection. But an experimental study is not done yet with COVID-19. Ayush-64 components have capable to reduce the viral and bacterial count from the human body. Hence, this drug is helpful to fight COVID-19.

Withania somnifera
Withania somnifera is also known as ashwagandha. A study suggests that Withania somnifera inhibits viral replication during the bursal disease. Bursal disease is a highly infectious disease of chickens. Another in-silico study suggests that Withania somnifera also acts as a replication inhibitor in COVID-19 infection and prevents COVID-19 entry in the host cell. Withania somnifera may be used as an alternative approach to prevent the COVID-19 infection but needs detailed experimental work. Withania somnifera was used as anti-diabetic herb in India. Coronil kit contains Withania somnifera and was used for COVID-19 infections because human blood sugar level was increased during COVID-19 infection.

Glycyrrhiza glabra
Glycyrrhiza glabra is a well-known medicinal herb. It is also used to control respiratory illness and viral infection. Glycyrrhiza glabra contains the glycyrrhizin compound as the pharmacologically active agent. Glycyrrhizin plays a major role for controlling the cellular damage of hepatitis B and C infection. A study
suggests that glycyrrhizin is also used as an antiviral drug in SARS infection. Its mechanism of action is based on inhibiting the viral replication in the host cell.\(^{(47)}\) Another \textit{in-silico} study suggests that glycyrrhiza may be used as a possible replication inhibitor in COVID-19 infection.\(^{(48)}\) \textit{Glycyrrhiza glabra} may be an alternative approach for preventing the COVID-19 infection.

\textbf{\textit{Alium sativum}}

\textit{A. sativum}, a popular herb in India, is mainly used for the treatment of fungal and viral infections. Its extract is known as ajoene. A study suggests that ajoene worked as a protective agent against HIV infection. It protected the CD\(^+\) cell during HIV infection at an early stage.\(^{(49-52)}\) \textit{A. sativum} may be used in COVID-19 as a supportive agent due to the antiviral properties but an experimental study against COVID-19 infection has not been reported yet.

\textbf{\textit{Phyllanthus emblica}}

\textit{P. emblica} is known as Amla and belongs to the \textit{Euphorbiaceae} family. \textit{P. emblica} fruit is mainly used to prevent the infection from HIV-1 and also showed protective action against the hepatitis B virus and influenza virus.\(^{(49)}\) It has been thought to provide support against COVID-19 infection by acting as an immunity booster. However, in the literature, there is no data regarding the \textit{in vivo} and \textit{in vitro} studies against COVID-19.

\textbf{\textit{Coronil}}

\textit{Coronil} is an Ayurvedic drug formed by Patanjali Research Insitute, India. It is available as a kit form. It contains multiple components like \textit{Withania somniferais}, \textit{Tinospora cordifolia}, \textit{Ocimum sanctum}, \textit{Cassia fistula}, \textit{Piper nigrum}, and \textit{Eclipta alba}. \textit{W. somniferais} provides help to control the blood sugar and \textit{Tinospora cordifolia} works against chronic fever and also helps to improve immunity and remaining components provide help to reduce inflammation and improve the lungs conditions. Thus, this Ayurvedic medicine is helpful to improve the human health system during COVID-19 infection. This kit was used against 367 patients suffering from COVID-19 infection in India then approx 67\% of patients were recovered from COVID-19.\(^{(45)}\)

\textbf{\textit{Ayush Kwath}}

\textit{Ayush kwath}, a mixture of ayurvedic herbs, is another effective medicine against COVID-19 in India. It contains \textit{Ocimum sanctum}, \textit{Cinnamomum zeylanicum}, \textit{Piper nigrum}, and \textit{Zingiber officinale}. These components help to reduce chronic fever and inflammation from the lungs and also work as immune boosters.\(^{(53)}\) Hence, this product is used against the COVID-19 in India as an immune booster. \textit{Ayush Kwath} provides protection not only for COVID-19 but also for other diseases like malaria, common cold, etc.

\textbf{\textit{Samshamani vati}}

\textit{Samshamani vati} is a well-known ayurvedic drug in India. It contains \textit{T. cardifolia} extract and is highly used against fever conditions. It has anti-inflammatory and anti-asthmatic properties which are highly useful against COVID-19. It is also helpful to aginst the various type of viral infection.\(^{(54)}\)

\textbf{\textit{CM}}

\textit{CM} is recommended for COVID-19 patients by the National Health Commission of the People’s Republic of China. Thousands of people are recovered from COVID-19 infection by CM treatment in China.\(^{(55)}\) Various \textit{CM} could be available for COVID-19 infection like Qingfei Paidu Decoction, Yupingfeng Powder, Huoxiang Zhengqi, and Lianhua Qingwen Capsule, etc. Qingfei Paidu Decoction and Yupingfeng are effective for COVID-19 and have more than 90\% effective rates.\(^{(40)}\) These drugs help to control the inflammation and improve human immunity during COVID-19 infection. \textit{CM} mainly works for enhancing human immunity and controlling the inflammation in the lungs. Hence \textit{CM} is a very useful medicine during COVID-19 throughout the world (Table 1).

\textbf{Integrating Allopathic and Other Traditional Medicines for Effective Therapy}

In the COVID-19 pandemic, allopathic and traditional medicine should be integrated. Doctors utilized both medicines simultaneously to treat COVID-19 patients. Many countries integrated traditional medicine during this pandemic into their health systems. Traditional medicines were used in combination or as alternatives to allopathic medicines to manage COVID-19 infection more effectively because traditional medicine is a major healthcare provider entity around the globe particularly in remote and rural areas. A large group of people is dependent on traditional medicines for their primary healthcare mainly in developing and underdeveloped countries and areas. Indian traditional medicinal
systems (Ayurveda, Siddha, and Unani) and Chinese traditional medical systems have a very rich history, and from time to time research findings acknowledged the importance of such systems because herbs are a vital source of novel potent therapeutic molecules.

A study was performed to know the interaction of herbs and chemical drugs.\(^{56}\) Herb *Hypericum perforatum* lowers concentrations of amitriptyline, cyclosporin, digoxin, indinavir, theophylline, and warfarin in blood. *Panax ginseng* (ginseng) lowers blood concentrations of alcohol and warfarin. *Allium sativum* (garlic) changes pharmacokinetic variables of paracetamol.\(^{57}\) Some herbal medicines are given to COVID-19 patients along with allopathic drugs for better recovery. In this way, the treatment pattern during this pandemic situation give a learning and further indication towards integration of allopathic and traditional medicine that is highly affordable and provides an opportunity to address some of the challenges in the treatment of disease. Many herbs interact with the chemical moiety of the drug and they enhance their bio-availability, but sometimes herbs' interaction is negative where they produce toxic effects after interacting with chemical substances. It causes such actions which are sometimes beneficial and sometimes detrimental to health. Pros and cons are always associated with any issue and this needs to be taken care of. It warrants more research on these issues so that the adverse events of combination of herbal and chemical drugs can be monitored and integrations are promoted to refrain from such practices. Several steps have been taken to promote such traditional medicines into clinical practice. Hopefully, incorporation and integration of traditional medicines with allopathy in clinical practice will help to provide quality healthcare to all.

**Conclusions**

In the current scenario, mankind is going through a serious problem due to COVID-19 and despite incredible advances in modern science and technology, allopathic medicine is unable to provide satisfactory treatment for COVID-19. Therefore, we should think to adopt such a holistic approach of integration of allopathy and traditional medicine for the diagnosis and treatment of the disease more effectively. To date, there is no precise single drug or combinatorial therapy for the prevention of COVID-19 infection. Hopefully, the other potential therapy will be available soon against COVID-19 infection, but it would be always better and could be the best practice to use allopathy and traditional medicine for mankind. At the current time, any effective chemical drug is not available to cure COVID-19, and available chemical drugs show very high side effects and limitations on the human body known post-COVID-19 effects. The available chemical drug can reduce the specific symptoms like inflammation and fever, but not perform multiple actions in the human body during the COVID-19 infection. Thus, the lack of drugs is responsible for the high mortality rate throughout the world. Hence, there is an urgent need of effective therapy to control COVID-19 infection. Thoughtful integration of these two treatment systems could expand the treatment workforce. Successful integration of traditional/allopathic medicine will help patients and the health care system to walk together to address the current global problem effectively. Integration of two therapies (traditional/allopathic) may be an effective key to control COVID-19 infection but it requires more experimental works to find the appropriate drugs and integration of drugs therapies.

**Conflict of Interest**

All authors declare that they have no conflict of interest.

**Author Contributions**

Aditya U: information collection, design, writing manuscript draft; Gopal P: design, draft writing; Dharm P: design, draft writing; Awanish K: conceptualization, design, and finalize manuscript.

**Acknowledgments**

Authors are grateful to the National Institute of Technology, Raipur (CG), India and Zhejiang Chinese Medical University, China.

**REFERENCES**

1. Jartti T, Jartti L, Ruuskanen O, Söderlund-Venermo M. New respiratory viral infections. *Curr Opin Pulm Med* 2012;18:271-278.
2. Singh T. A review of coronavirus disease—2019 (COVID-19). *Ind J Pediatr* 2020;87:281-286.
3. Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. *Int J Antimicrob Agents* 2020;55:105948.
4. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. *J Clin Med* 2020;24:9:1225.
5. Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M, et al. COVID-19 transmission, current treatment, and future therapeutic strategies. *Mol Pharm* 2021;18:754-771.
6. Kumar SU, Priya NM, Nithya SR, Kannan P, Jain N, Kumar DT, et al. A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current sheds of evidence, candidate vaccines, and drug repurposing. Biotechnol 2021;11:198.
7. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B 2020;21:343-360.
8. Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens (Basel, Switzerland) 2020;9:337.
9. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-273.
10. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276-278.
11. Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9:221-236.
12. Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus. J Med Virol 2020;92:521-528.
13. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbes 2020;27:325-328.
14. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J Virol 2005;79:5288-5298.
15. Li W, Moore MJ, Vasilieva N, Sui J, Wang SY, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-454.
16. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020;5:562-569.
17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
18. Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol 2012;2:264-275.
19. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health 2020;13:667-673.
20. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020;324:782-793.
21. Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al. COVID-19: a multidisciplinary review. Public Health Front 2020;8:383.
22. Almaghaslah D, Kandasamy G, Almanasef M, Vasudevan R, Chandramohan S. Review on the coronavirus disease (COVID-19) pandemic: its outbreak and current status. Int J Clin Pract 2020;74:e13637.
23. Wu R, Wang L, Kuo H-CD, Shannah A, Peter R, Chou PJ, et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmocol Rep 2020;6:56-70.
24. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155-166.
25. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 2003;3:722-727.
26. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol 2020;12:322-325.
27. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72-73.
28. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018;9:e00221-18.
29. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020;295:4773-4779.
30. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy 2020;40:416-437.
31. Villalain J. Membranotropic effects of Arbidol, a broad antiviral molecule, on phospholipid model membranes. J Phys Chem B 2010;114:8544-8554.
32. Furuta Y, Komoto T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad B: Phys Biol Sci 2017;93:449-463.
33. McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs 2001;61:263-283.
34. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63:769-802.
Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir/Ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Kor Med Sci 2020;35:e79.

37. Owa AB, Owa OT. Lopinavir/ritonavir use in COVID-19 infection: is it completely non-beneficial? J Microbiol Immunol Infect 2020;53:674-675.

38. Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: a systematic review and a clinician’s perspective. Diabetes Metab Syndr 2020;14:971-978.

39. Pinzón MA, Ortiz S, Holguín H, Betancur JF, Cardona Arango D, Laniado H, et al. Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia. PLoS One 2021;16:e0252057.

40. Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med 2020;26:243-250.

41. Kazim M, Puri SK, Dutta GP, Narasimham MV. Evaluation of Ayush-64 for blood schizontocidal activity against rodent and simian malaria parasites. Ind J Malarol 1991;28:255-258.

42. Gundeti MS, Bhurke LW, Mundada PS, Murudkar S, Surve A, Sharma R, et al. Ayush 64, a polyherbal Ayurvedic formulation in influenza-like illness—results of a pilot study. J Ayurv Integr Med 2020;S0975-9476:30025-5.

43. Ganguly B, Umapathi V, Rastogi SK. Nitric oxide induced by Indian ginseng root extract inhibits infectious bursal disease virus in chicken embryo fibroblasts in vitro. J Anim Sci Technol 2018;60:2.

44. Borse S, Joshi M, Saggam A, Bhat V, Walia S, Marathe A, et al. Ayurveda botanicals in COVID-19 management: an in silico multi-target approach. PLoS One 2021;16:e0248479.

45. Balkrishna A, Raj P, Singh P, Varshney A. Influence of patient-reported treatment satisfaction on psychological health and quality of life among receiving Divya-Swasari-Coronil-Kit against COVID-19: findings from a cross-sectional “Satisfaction COVID” survey. Patient Prefer Adherence 2021;15:899-909.

46. Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D, et al. Antiviral effects of Glycyrrhiza species. Phytother Res 2008;22:141-148.

47. Cinat J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003;361:2045-2046.

48. Sinha SK, Prasad SK, Islam MA, Gurav SS, Patil RB, AlFaris NA, et al. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study. J Biomol Struct Dyn 2021;39:4686-4700.

49. Arora R, Chawla R, Marwah R, Arora P, Sharma RK, Kaushik V, et al. Potential of complementary and alternative medicine in preventive management of novel H1N1 flu (Swine Flu) pandemic: thwarting potential disasters in the bud. Evid Based Complement Alternat Med 2011:2011:586506.

50. Rishi P, Thakur K, Vij S, Rishi L, Singh A, Kaur IP, et al. Diet, gut microbiota and COVID-19. Ind J Microbiol 2020;60:1-10.

51. Patel SKS, Lee JK, Kalia VC. Deploying biomolecules as anti-COVID-19 agents. Ind J Microbiol 2020;60:263-268.

52. Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev 2020;53:66-70.

53. Gautam S, Gautham A, Chhetri S, Bhattarai U. Immunity against COVID-19: potential role of Ayush Kwath. J Ayurv Integ Med 2022;13:100350.

54. Sachan S, Dhama K, Latheef SK, Samad HA, Mariappan AK, Munuswamy P, et al. Immunomodulatory potential of tinospora cordifolia and CpG ODN (TLR21 agonist) against the very virulent, infectious bursal disease virus in SPF chicks. Vaccines (Basel) 2019;7:106.

55. Qing GC, Zhang H, Bai Y, Luo Y. Traditional Chinese and Western medicines jointly beat COVID-19 pandemic. Chin J Integr Med 2020;26:403-404.

56. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001;61:2163-2175.

57. Piscitelli SC, Burstine AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234-238.

(Accepted October 28, 2021; First Online May 4, 2022)

Edited by WANG Wei-xia